SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Background Rapid increases in cases of COVID-19 were observed in multiple cities in Iran towards the start of the pandemic. However, the true infection rate remains unknown. We aimed to assess the seroprevalence of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 18 cities of Iran as an indicator of the infection rate. Methods In this population-based cross-sectional study, we randomly selected and invited study participants from the general population (from lists of people registered with the Iranian electronic health record system or health-care centres) and a high-risk population of individuals likely to have close social contact with SARS-CoV-2-infected individuals through their occupation (from employee lists provided by relevant agencies or companies, such as supermarket chains) across 18 cities in 17 Iranian provinces. Participants were asked questions on their demographic characteristics, medical history, recent COVID-19-related symptoms, and COVID-19-related exposures. Iran Food and Drug Administration-approved Pishtaz Teb SARS-CoV-2 ELISA kits were used to detect SARS-CoV-2-specific IgG and IgM antibodies in blood samples from participants. Seroprevalence was estimated on the basis of ELISA test results and adjusted for population weighting (by age, sex, and city population size) and test performance (according to our independent validation of sensitivity and specificity). Findings From 9181 individuals who were initially contacted between April 17 and June 2, 2020, 243 individuals refused to provide blood samples and 36 did not provide demographic information and were excluded from the analysis. Among the 8902 individuals included in the analysis, 5372 had occupations with a high risk of exposure to SARS-CoV-2 and 3530 were recruited from the general population. The overall population weight-adjusted and test performance-adjusted prevalence of antibody seropositivity in the general population was 17·1% (95% CI 14·6–19·5), implying that 4 265 542 (95% CI 3 659 043–4 887 078) individuals from the 18 cities included were infected by the end of April, 2020. The adjusted seroprevalence of SARS-CoV-2-specific antibodies varied greatly by city, with the highest estimates found in Rasht (72·6% [53·9–92·8]) and Qom (58·5% [37·2–83·9]). The overall population weight-adjusted and test performance-adjusted seroprevalence in the high-risk population was 20·0% (18·5–21·7) and showed little variation between the occupations included. Interpretations Seroprevalence is likely to be much higher than the reported prevalence of COVID-19 based on confirmed COVID-19 cases in Iran. Despite high seroprevalence in a few cities, a large proportion of the population is still uninfected. The potential shortcomings of current public health policies should therefore be identified to prevent future epidemic waves in Iran. Funding Iranian Ministry of Health and Medical Education. Translation For the Farsi translation of the abstract see Supplementary Materials section.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bootstrap methods: another look at the jackknife
Efron, B. (1979) · The Annals of Statistics · doi:10.1214/aos/1176344552 · Cited by 17,602
Wu, Z., & McGoogan, J. M. (2020) · JAMA · doi:10.1001/jama.2020.2648 · Cited by 17,016
Chu, D. K., Akl, E. A., Duda, S., Solo, K., Yaacoub, S., Schünemann, H. J., Chu, D. K., Akl, E. A., El-harakeh, A., Bognanni, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31142-9 · Cited by 3,843
Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis
Rodriguez-Morales, A. J., Cardona-Ospina, J. A., Gutiérrez-Ocampo, E., Villamizar-Peña, R., Holguin-Rivera, Y., Escalera-Antezana, J. P., Alvarado-Arnez, L. E., Bonilla-Aldana, D. K., Franco-Paredes, C., Henao-Martinez, A. F., et al. (2020) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2020.101623 · Cited by 2,542
Pollán, M., Pérez-Gómez, B., Pastor-Barriuso, R., Oteo, J., Hernán, M. A., Pérez-Olmeda, M., Sanmartín, J. L., Fernández-García, A., Cruz, I., Fernández de Larrea, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31483-5 · Cited by 1,639
Cited by
Hansen, C. H., Michlmayr, D., Gubbels, S. M., Mølbak, K., & Ethelberg, S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00575-4 · Cited by 586
Levin, A. T., Owusu-Boaitey, N., Pugh, S., Fosdick, B. K., Zwi, A. B., Malani, A., Soman, S., Besançon, L., Kashnitsky, I., Ganesh, S., et al. (2022) · BMJ Global Health · doi:10.1136/bmjgh-2022-008477 · Cited by 208
Gozzi, N., Tizzoni, M., Chinazzi, M., Ferres, L., Vespignani, A., & Perra, N. (2021) · Nature Communications · doi:10.1038/s41467-021-22601-6 · Cited by 142
Vial, P., González, C., Icaza, G., Ramirez-Santana, M., Quezada-Gaete, R., Núñez-Franz, L., Apablaza, M., Vial, C., Rubilar, P., Correa, J., et al. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07045-7 · Cited by 31
Metadata
- Authors
- Poustchi, H., Darvishian, M., Mohammadi, Z., Shayanrad, A., Delavari, A., Bahadorimonfared, A., Eslami, S., Javanmard, S. H., Shakiba, E., Somi, M. H., Emami, A., Saki, N., Hormati, A., Ansari-Moghaddam, A., Saeedi, M., Ghasemi-Kebria, F., Mohebbi, I., Mansour-Ghanaei, F., Karami, M., Sharifi, H., Pourfarzi, F., Veisi, N., Ghadimi, R., Eghtesad, S., Niavarani, A., Ali Asgari, A., Sadeghi, A., Sorouri, M., Anushiravani, A., Amani, M., Kaveh, S., Feizesani, A., Tabarsi, P., Keyvani, H., Markarian, M., Shafighian, F., Sima, A., Sadjadi, A., Radmard, A. R., Mokdad, A. H., Sharafkhah, M., & Malekzadeh, R.
- Venue
- The Lancet Infectious Diseases
- Publisher
- Elsevier BV
- Published
- 2021-04
- Volume
- 21
- Issue
- 4
- Pages
- 473-481
- ISSN
- 1473-3099 (ISSN-L)
- OpenAlex
- W3111967471
- Cited by
- 164
- References
- 5
- FWCI
- 4.29
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study. https://app.cochat.ai/papers/10.1016/s1473-3099(20)30858-6
- The paper
- Poustchi, H., Darvishian, M., Mohammadi, Z., Shayanrad, A., Delavari, A., Bahadorimonfared, A., Eslami, S., Javanmard, S. H., Shakiba, E., Somi, M. H., Emami, A., Saki, N., Hormati, A., Ansari-Moghaddam, A., Saeedi, M., Ghasemi-Kebria, F., Mohebbi, I., Mansour-Ghanaei, F., Karami, M., . . . Malekzadeh, R. (2021). SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(20)30858-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.